OQROGet OQRO Pro
Insider trade

Kalaris Therapeutics (KLRS)Chief Accounting Officer sold ~$13K

Brett R Hagen, Chief Accounting Officer at Kalaris Therapeutics, sold ~$13K of Kalaris Therapeutics shares.

~$13K
Approx. value · 1,915 sh @ $6.72
Traded
Mar 20, 2026
Filed
Mar 23, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Dec 18, 2025Insider · First insider buy since Jun 2023Director purchased ~$5M of KLRS shares in the open market
  2. Mar 17, 2026Company filing · Form 8-K · ResultsReported its results
  3. Mar 20, 2026 · this disclosureInsiderOfficer sold ~$13K of KLRS shares in the open market

What came next

  1. Apr 8, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 8, 2026, Matthew Gall notified Kalaris Therapeutics, Inc. (the “Company”) of his decision to resign as the Chief Financial Officer of the Company, effective April 14, 2026 (the “Separation Date”).”
  2. May 12, 2026Company filing · Form 8-K · ResultsReported its results
  3. May 20, 2026InsiderDirector purchased ~$1.18M of KLRS shares in the open market
  4. Jul 3, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On July 3, 2026, Morana Jovan-Embiricos, Ph.D., notified Kalaris Therapeutics, Inc. (the “Company”) of her decision to resign as a member of the Company’s board of directors (the “Board”), effective immediately.”
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Kalaris Therapeutics

OQRO holds no insider, Congress, fund or contract record for Kalaris Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its KLRS page.

Other recent filings by Brett R Hagen, Chief Accounting Officer

The full history of Brett R Hagen, Chief Accounting Officer is on the profile page.

How this filing works

Other disclosures at Kalaris Therapeutics

Everything OQRO holds on this company is on its KLRS page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data